The estimated Net Worth of Jennifer K. Simpson is at least $373 Thousand dollars as of 30 January 2023. Dr Simpson owns over 4,444 units of Panbela Therapeutics stock worth over $2,754 and over the last 13 years he sold PBLA stock worth over $0. In addition, he makes $369,924 as CEO and Pres & Director at Panbela Therapeutics.
Dr has made over 4 trades of the Panbela Therapeutics stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 4,444 units of PBLA stock worth $1,555 on 30 January 2023.
The largest trade he's ever made was buying 7,399 units of Panbela Therapeutics stock on 28 September 2018 worth over $12,948. On average, Dr trades about 598 units every 156 days since 2012. As of 30 January 2023 he still owns at least 7,868 units of Panbela Therapeutics stock.
You can see the complete history of Dr Simpson stock trades at the bottom of the page.
Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D. is the CEO, Pres & Director at Panbela Therapeutics.
As the CEO and Pres & Director of Panbela Therapeutics, the total compensation of Dr D at Panbela Therapeutics is $369,924. There are no executives at Panbela Therapeutics getting paid more.
Dr D is 53, he's been the CEO and Pres & Director of Panbela Therapeutics since . There are 2 older and no younger executives at Panbela Therapeutics. The oldest executive at Panbela Therapeutics Inc. is Dr. Suzanne Gagnon, 64, who is the Chief Medical Officer & Director.
Jennifer's mailing address filed with the SEC is 712 VISTA BLVD #305, , WACONIA, MN, 55387.
Over the last 4 years, insiders at Panbela Therapeutics have traded over $51,741 worth of Panbela Therapeutics stock and bought 406,888 units worth $0 . The most active insiders traders include Sachs Group Incgoldman Sach..., Donald Robert Schemel, and Michael T. Cullen. On average, Panbela Therapeutics executives and independent directors trade stock every 67 days with the average trade being worth of $27,986. The most recent stock trade was executed by Sachs Group Incgoldman Sach... on 8 November 2023, trading 72,874 units of PBLA stock currently worth $51,741.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
Panbela Therapeutics executives and other stock owners filed with the SEC include: